BETA Beta Drugs Q2 FY26 results (Jul–Sep 2025) and concall
Beta Drugs Ltd reported a solid H1 FY26 with 13% revenue growth and 17% EBITDA growth, driven by strategic market entries and backward integration. Despite a slight dip in gross margins due to product mix and H1 growth being below annual targets, management expects a strong H2, particularly in exports, and is progressing on regulatory approvals and new product launches, including biosimilars.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
| Line item | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|
| Revenue | 48 | 54 | 66 | 54 |
| EBITDA | 6 | 5 | 8 | 5 |
| Net profit | 1 | 1 | 4 | 2 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
